CV 205-502(八氢苯并喹啉Octahydrobenzo(g)quinoline),是一新的长效非麦角类多巴胺激动剂。动物试验表明能抑制PRL的分泌,效力(?)为溴隐亭的35倍,且作用时间较长。本文首次报告以CV205-502为高泌乳素血症(hPRL)患者进行短期治疗的双盲研究结果。受试者为24名hPRL患者(18～47岁),曾有闭经史(6～132月)。其中21例曾服用溴隐亭。但参加研究前已停药至少一个月,此时8例闭经,7例月经稀发,9例月经规则。蝶鞍断层及平片检查14例异常。19例曾行CT检查垂体瘤,鞍外扩张或空鞍症。全组皆无其它内分泌系统疾患。24例患者 CV 205-502 (Octahydrobenzo (g) quinoline) is a new long-acting non-ergot dopamine agonist. Animal experiments showed that PRL secretion can be inhibited, the potency (?) Is 35 times bromocriptine, and the role of longer. This is the first report of a double-blind study of short-term treatment of patients with hyperprolactinemia (hPRL) using CV205-502. The subjects were 24 hPRL patients (18-47 years) who had a history of amenorrhea (6-13 months). Of these, 21 had bromocriptine. However, before taking part in the study has been discontinued at least one month, then 8 cases of amenorrhea, 7 cases of menstruation thin hair, 9 cases of menstrual rules. Sella fault and plain film examination of 14 cases of abnormalities. 19 cases had CT examination of pituitary tumor, extra-saddle or empty saddle. The whole group had no other endocrine system disorders. 24 patients